
Giovanni A Fava

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3204782/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Allostatic Load and Its Impact on Health: A Systematic Review. Psychotherapy and Psychosomatics, 2021, 90, 11-27.	8.8	441
2	The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychotherapy and Psychosomatics, 2016, 85, 270-288.	8.8	428
3	Diagnostic Criteria for Use in Psychosomatic Research. Psychotherapy and Psychosomatics, 1995, 63, 1-8.	8.8	329
4	Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychotherapy and Psychosomatics, 2015, 84, 72-81.	8.8	319
5	Six-Year Outcome of Cognitive Behavior Therapy for Prevention of Recurrent Depression. American Journal of Psychiatry, 2004, 161, 1872-1876.	7.2	299
6	Development and characteristics of a well-being enhancing psychotherapeutic strategy: well-being therapy. Journal of Behavior Therapy and Experimental Psychiatry, 2003, 34, 45-63.	1.2	293
7	Increasing Psychological Wellâ€Being and Resilience by Psychotherapeutic Methods. Journal of Personality, 2009, 77, 1903-1934.	3.2	293
8	Well-Being Therapy of Generalized Anxiety Disorder. Psychotherapy and Psychosomatics, 2005, 74, 26-30.	8.8	292
9	Subclinical symptoms in mood disorders: pathophysiological and therapeutic implications. Psychological Medicine, 1999, 29, 47-61.	4.5	260
10	Psychiatric Disorders Associated with Cushing??s Syndrome. CNS Drugs, 2001, 15, 361-373.	5.9	219
11	Current Psychosomatic Practice. Psychotherapy and Psychosomatics, 2017, 86, 13-30.	8.8	205
12	Staging of Mental Disorders: Systematic Review. Psychotherapy and Psychosomatics, 2013, 82, 20-34.	8.8	185
13	Can Long-Term Treatment With Antidepressant Drugs Worsen the Course of Depression?. Journal of Clinical Psychiatry, 2003, 64, 123-133.	2.2	185
14	The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry, 2020, 19, 269-293.	10.4	174
15	Clinical characterization of allostatic overload. Psychoneuroendocrinology, 2019, 108, 94-101.	2.7	172
16	The Concept of Euthymia. Psychotherapy and Psychosomatics, 2016, 85, 1-5.	8.8	158
17	Methodological Recommendations for Trials of Psychological Interventions. Psychotherapy and Psychosomatics, 2018, 87, 276-284.	8.8	146
18	The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. BMC Medicine, 2018, 16, 112.	5.5	143

#	Article	IF	CITATIONS
19	Efficacy and Tolerability of Benzodiazepines versus Antidepressants in Anxiety Disorders: A Systematic Review and Meta-Analysis. Psychotherapy and Psychosomatics, 2013, 82, 355-362.	8.8	138
20	The Sequential Combination of Cognitive Behavioral Treatment and Well-Being Therapy in Cyclothymic Disorder. Psychotherapy and Psychosomatics, 2011, 80, 136-143.	8.8	136
21	Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychotherapy and Psychosomatics, 2018, 87, 195-203.	8.8	133
22	The Hamilton Rating Scales for Depression: A Critical Review of Clinimetric Properties of Different Versions. Psychotherapy and Psychosomatics, 2020, 89, 133-150.	8.8	133
23	Psychometric Theory Is an Obstacle to the Progress of Clinical Research. Psychotherapy and Psychosomatics, 2004, 73, 145-148.	8.8	127
24	The mechanisms of tolerance in antidepressant action. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1593-1602.	4.8	123
25	The Clinical Process in Psychiatry. Journal of Clinical Psychiatry, 2012, 73, 177-184.	2.2	118
26	The Sequential Integration of Pharmacotherapy and Psychotherapy in the Treatment of Major Depressive Disorder: A Meta-Analysis of the Sequential Model and a Critical Review of the Literature. American Journal of Psychiatry, 2016, 173, 128-137.	7.2	117
27	The Clinimetric Approach to Psychological Assessment: A Tribute to Per Bech, MD (1942–2018). Psychotherapy and Psychosomatics, 2018, 87, 321-326.	8.8	112
28	Clinical Assessment of Allostatic Load and Clinimetric Criteria. Psychotherapy and Psychosomatics, 2010, 79, 280-284.	8.8	107
29	The pursuit of euthymia. World Psychiatry, 2020, 19, 40-50.	10.4	104
30	The Road to Recovery from Depression – Don't Drive Today with Yesterday's Map. Psychotherapy and Psychosomatics, 2007, 76, 260-265.	8.8	103
31	The Concept of Recovery in Affective Disorders. Psychotherapy and Psychosomatics, 1996, 65, 2-13.	8.8	102
32	Long-Term Effects of Behavioural Treatment for Panic Disorder with Agoraphobia. British Journal of Psychiatry, 1995, 166, 87-92.	2.8	99
33	Excessive Mood Elevation and Behavioral Activation with Antidepressant Treatment of Juvenile Depressive and Anxiety Disorders: A Systematic Review. Psychotherapy and Psychosomatics, 2013, 82, 132-141.	8.8	86
34	Cognitive Behavior Approach to Loss of Clinical Effect During Long-Term Antidepressant Treatment: A Pilot Study. American Journal of Psychiatry, 2002, 159, 2094-2095.	7.2	84
35	Clinimetric Criteria for Patient-Reported Outcome Measures. Psychotherapy and Psychosomatics, 2021, 90, 222-232.	8.8	84
36	Psychological Factors Affecting Medical Condition: A New Proposal for DSM-V. Psychosomatics, 2007, 48, 103-111.	2.5	81

3

#	Article	IF	CITATIONS
37	Rational Use of Antidepressant Drugs. Psychotherapy and Psychosomatics, 2014, 83, 197-204.	8.8	80
38	The clinical role of well-being therapy. Nordic Journal of Psychiatry, 2018, 72, 447-453.	1.3	79
39	Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder. JAMA Psychiatry, 2021, 78, 261.	11.0	77
40	Rating well-being and distress. Stress and Health, 2000, 16, 55-61.	0.5	76
41	The Clinical Interview for Depression: A Comprehensive Review of Studies and Clinimetric Properties. Psychotherapy and Psychosomatics, 2011, 80, 10-27.	8.8	75
42	The Clinical Inadequacy of the Placebo Model and the Development of an Alternative Conceptual Framework. Psychotherapy and Psychosomatics, 2017, 86, 332-340.	8.8	75
43	The Clinical Domains of Psychosomatic Medicine. Journal of Clinical Psychiatry, 2005, 66, 849-858.	2.2	74
44	Sequential Treatment of Mood and Anxiety Disorders. Journal of Clinical Psychiatry, 2005, 66, 1392-1400.	2.2	74
45	Psychosomatic Assessment. Psychotherapy and Psychosomatics, 2009, 78, 333-341.	8.8	73
46	The Intellectual Crisis of Psychiatric Research. Psychotherapy and Psychosomatics, 2006, 75, 202-208.	8.8	72
47	Do Antidepressanf and Antianxiety Drugs Increase Chronicity in Affective Disorders?. Psychotherapy and Psychosomatics, 1994, 61, 125-131.	8.8	69
48	Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. International Journal of Neuropsychopharmacology, 2007, 10, 835-8.	2.1	67
49	Prodromal stage of major depression. Microbial Biotechnology, 2007, 1, 9-18.	1.7	66
50	New Modalities of Assessment and Treatment Planning in Depression. CNS Drugs, 2010, 24, 453-465.	5.9	64
51	latrogenic Factors in Psychopathology. Psychotherapy and Psychosomatics, 2019, 88, 129-140.	8.8	64
52	Well-Being Therapy: Current Indications and Emerging Perspectives. Psychotherapy and Psychosomatics, 2016, 85, 136-145.	8.8	63
53	Well-being therapy in depression: New insights into the role of psychological well-being in the clinical process. Depression and Anxiety, 2017, 34, 801-808.	4.1	61
54	The Spectrum of Anxiety Disorders in the Medically Ill. Journal of Clinical Psychiatry, 2010, 71, 910-914.	2.2	57

#	Article	IF	CITATIONS
55	Evidence-based medicine was bound to fail: a report to Alvan Feinstein. Journal of Clinical Epidemiology, 2017, 84, 3-7.	5.0	56
56	Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review. Psychotherapy and Psychosomatics, 2018, 87, 65-74.	8.8	56
57	Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience. Psychotherapy and Psychosomatics, 2018, 87, 257-267.	8.8	56
58	A role for life events in the pathogenesis of Cushing's disease. Clinical Endocrinology, 1993, 38, 261-264.	2.4	53
59	The Clinical Inadequacy of Evidence-Based Medicine and the Need for a Conceptual Framework Based on Clinical Judgment. Psychotherapy and Psychosomatics, 2015, 84, 1-3.	8.8	53
60	Behavioral Toxicity Revisited. Journal of Clinical Psychopharmacology, 2016, 36, 550-553.	1.4	47
61	Treatment of Recurrent Depression. CNS Drugs, 2003, 17, 1109-1117.	5.9	46
62	The clinical inadequacy of the DSM-5 classification of somatic symptom and related disorders: an alternative trans-diagnostic model. CNS Spectrums, 2016, 21, 310-317.	1.2	45
63	Mental Pain as a Transdiagnostic Patient-Reported Outcome Measure. Psychotherapy and Psychosomatics, 2019, 88, 341-349.	8.8	44
64	Depression Associated with Medical Illness. CNS Drugs, 1996, 5, 175-189.	5.9	43
65	Clinical Pharmacopsychology: Conceptual Foundations and Emerging Tasks. Psychotherapy and Psychosomatics, 2017, 86, 134-140.	8.8	42
66	Agoraphobia Is a Disease: A Tribute to Sir Martin Roth. Psychotherapy and Psychosomatics, 2008, 77, 133-138.	8.8	41
67	Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. Pituitary, 2000, 3, 55-59.	2.9	40
68	A discussion on the role of clinimetrics and the misleading effects of psychometric theory. Journal of Clinical Epidemiology, 2005, 58, 753-756.	5.0	40
69	Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 40, 306-311.	4.8	40
70	Psychological aspects of endocrine disease. Clinical Endocrinology, 1998, 49, 1-7.	2.4	39
71	Psychological Characterization of Demoralization in the Setting of Heart Transplantation. Journal of Clinical Psychiatry, 2011, 72, 648-654.	2.2	39
72	May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532097032.	2.7	36

#	Article	IF	CITATIONS
73	Management of Recurrent Depression in Primary Care. Psychotherapy and Psychosomatics, 2003, 72, 3-9.	8.8	32
74	Psychosomatic Medicine is a Comprehensive Field, Not a Synonym for Consultation Liaison Psychiatry. Current Psychiatry Reports, 2010, 12, 215-221.	4.5	32
75	The Missing Link between Clinical States and Biomarkers in Mental Disorders. Psychotherapy and Psychosomatics, 2014, 83, 136-141.	8.8	32
76	From the Lesson of George Engel to Current Knowledge: The Biopsychosocial Model 40 Years Later. Psychotherapy and Psychosomatics, 2017, 86, 257-259.	8.8	32
77	Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs. Journal of Clinical Psychiatry, 2019, 80, .	2.2	32
78	The Role of Staging in Planning Psychotherapeutic Interventions in Depression. Journal of Clinical Psychiatry, 2017, 78, 456-463.	2.2	32
79	The Decline of Pharmaceutical Psychiatry and the Increasing Role of Psychological Medicine. Psychotherapy and Psychosomatics, 2009, 78, 220-227.	8.8	31
80	Treatment Selection in Depression: The Role of Clinical Judgment. Psychiatric Clinics of North America, 2012, 35, 87-98.	1.3	31
81	Sequential Combination of Cognitive-Behavioral Treatment and Well-Being Therapy in Depressed Patients with Acute Coronary Syndromes: A Randomized Controlled Trial (TREATED-ACS Study). Psychotherapy and Psychosomatics, 2020, 89, 345-356.	8.8	31
82	Financial conflicts of interest in psychiatry. World Psychiatry, 2007, 6, 19-24.	10.4	31
83	Psychological aspects of hyperandrogenic states in late adolescent and young women. Clinical Endocrinology, 2015, 83, 872-878.	2.4	30
84	The Decline of Pluralism in Medicine: Dissent Is Welcome. Psychotherapy and Psychosomatics, 2020, 89, 1-5.	8.8	29
85	Kellner's Symptom Questionnaire, a Highly Sensitive Patient-Reported Outcome Measure: Systematic Review of Clinimetric Properties. Psychotherapy and Psychosomatics, 2020, 89, 74-89.	8.8	29
86	Irritable mood and physical illness. Stress and Health, 1987, 3, 293-299.	0.5	27
87	Clinical judgment in psychiatry. Requiem or reveille?. Nordic Journal of Psychiatry, 2013, 67, 1-10.	1.3	27
88	The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem. Psychotherapy and Psychosomatics, 2020, 89, 265-273.	8.8	27
89	When Anxiety and Depression Coexist: The Role of Differential Diagnosis Using Clinimetric Criteria. Psychotherapy and Psychosomatics, 2021, 90, 308-317.	8.8	27
90	The emerging role of euthymia in psychotherapy research and practice. Clinical Psychology Review, 2020, 82, 101941.	11.4	26

#	Article	IF	CITATIONS
91	Benzodiazepines: it's time to return to the evidence. British Journal of Psychiatry, 2021, 218, 125-127.	2.8	26
92	Emerging clinical trends and perspectives on comorbid patterns of mental disorders in research. International Journal of Methods in Psychiatric Research, 2014, 23, 92-101.	2.1	25
93	The Clinical Science of Euthymia: A Conceptual Map. Psychotherapy and Psychosomatics, 2022, 91, 156-167.	8.8	25
94	Conceptual Obstacles to Research Progress in Affective Disorders. Psychotherapy and Psychosomatics, 1997, 66, 283-285.	8.8	24
95	Clinical Methodology Matters in Epidemiology: Not All Benzodiazepines Are the Same. Psychotherapy and Psychosomatics, 2015, 84, 262-264.	8.8	24
96	Prodromal Symptoms in Depression: A Systematic Review. Psychotherapy and Psychosomatics, 2021, 90, 365-372.	8.8	24
97	Treatment of recurrent depression. Expert Review of Neurotherapeutics, 2006, 6, 1735-1740.	2.8	20
98	The clinical role of psychological wellâ€being. World Psychiatry, 2012, 11, 102-103.	10.4	20
99	Clinical configuration of cyclothymic disturbances. Journal of Affective Disorders, 2012, 139, 244-249.	4.1	20
100	The Hidden Costs of Financial Conflicts of Interest in Medicine. Psychotherapy and Psychosomatics, 2016, 85, 65-70.	8.8	20
101	The Assessment of Allostatic Overload in Patients with Congestive Heart Failure by Clinimetric Criteria. Stress and Health, 2016, 32, 63-69.	2.6	20
102	Forty Years of Clinimetrics. Psychotherapy and Psychosomatics, 2022, 91, 1-7.	8.8	20
103	Assessment of subclinical symptoms and psychological well-being in depression. European Archives of Psychiatry and Clinical Neuroscience, 2001, 251, 47-52.	3.2	19
104	Road to nowhere. World Psychiatry, 2014, 13, 49-50.	10.4	18
105	Need for a realistic appraisal of benzodiazepines. World Psychiatry, 2015, 14, 243-244.	10.4	17
106	Family Intervention Approach to Loss of Clinical Effect During Long-Term Antidepressant Treatment. Journal of Clinical Psychiatry, 2007, 68, 1348-1351.	2.2	17
107	The mental health clinic: a new model. World Psychiatry, 2008, 7, 177-181.	10.4	16
108	Psychotherapy in recurrent depression: efficacy, pitfalls, and recommendations. Expert Review of Neurotherapeutics, 2020, 20, 1169-1175.	2.8	16

#	Article	IF	CITATIONS
109	Psychological reactions to fetoscopy: A controlled study. Prenatal Diagnosis, 1984, 4, 397-404.	2.3	14
110	Potential Sensitising Effects of Antidepressant Drugs on Depression. CNS Drugs, 1999, 12, 247-256.	5.9	14
111	The rise and fall and rise of benzodiazepines: a return of the stigmatized and repressed. Revista Brasileira De Psiquiatria, 2020, 42, 243-244.	1.7	13
112	The Diagnostic clinical Interview for Drug Withdrawal 1 (DID-W1) – New Symptoms of Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine Reuptake Inhibitors (SNRI): inter-rater reliability. Rivista Di Psichiatria, 2018, 53, 95-99.	0.6	13
113	Relapse prevention in recurrent major depressive disorder. A comparison of different treatment options based on clinical experience and a critical review of the literature. International Journal of Psychiatry in Clinical Practice, 2020, 24, 341-348.	2.4	12
114	The Sequential Combination of Pharmacotherapy and Psychotherapy in Mood Disorders. Journal of Contemporary Psychotherapy, 2009, 39, 101-109.	1.2	11
115	Psychosocial determinants of recovery in depression. Dialogues in Clinical Neuroscience, 2008, 10, 461-472.	3.7	11
116	Overcoming the Crisis of Clinical Research. Psychotherapy and Psychosomatics, 2018, 87, 1-4.	8.8	10
117	Conceptual and Clinical Innovations of Well-being Therapy. International Journal of Cognitive Therapy, 2021, 14, 196-208.	2.2	10
118	Benzodiazepines in Anxiety Disorders. JAMA Psychiatry, 2015, 72, 733.	11.0	9
119	An innovative approach to the assessment of mood disturbances in patients with acute coronary syndrome. CNS Spectrums, 2023, 28, 78-89.	1.2	9
120	The Independence of Medical Journals and the Deceptive Effects of Open Access. Psychotherapy and Psychosomatics, 2014, 83, 1-5.	8.8	8
121	The Journal's Mission. Psychotherapy and Psychosomatics, 2019, 88, 1-4.	8.8	8
122	An innovative approach for the assessment of mood disturbances in patients with eating disorders. CNS Spectrums, 2020, 25, 71-78.	1.2	8
123	Screening and Diagnosis of Depression. Disease Management and Health Outcomes, 1997, 2, 1-7.	0.4	7
124	New psychotherapeutic approaches to residual symptoms and relapse prevention in unipolar depression. Clinical Psychology and Psychotherapy, 1999, 6, 194-201.	2.7	7
125	What psychologists need to know about psychotropic medications. Clinical Psychology and Psychotherapy, 2018, 25, 181-187.	2.7	6
126	The Age of Transition. Psychotherapy and Psychosomatics, 2021, 90, 1-4.	8.8	6

#	Article	IF	CITATIONS
127	The Psychosomatic Practice. Acta Dermato-Venereologica, 2014, 96, 9-13.	1.3	5
128	Addressing Clinical Challenges of Antidepressant Discontinuation. American Journal of Psychiatry, 2019, 176, 487-488.	7.2	5
129	The Emerging Role of Clinical Pharmacopsychology. Clinical Psychology in Europe, 2019, 1, .	1.1	5
130	The Role of Psychological Well-Being in Weight Loss: New Insights from a Comprehensive Lifestyle Intervention. International Journal of Clinical and Health Psychology, 2022, 22, 100279.	5.1	5
131	Anxiety sensitivity in essential hypertension. Stress and Health, 1992, 8, 113-115.	0.5	4
132	Reply to the Letter to the Editor: "ls A Single-Item Measure of Self-Rated Mental Health Useful from a Clinimetric Perspective?― Psychotherapy and Psychosomatics, 2019, 88, 179-179.	8.8	4
133	Rating wellâ€being and distress. Stress and Health, 2000, 16, 55-61.	0.5	4
134	Time to rethink the approach to recurrent depression. Lancet Psychiatry, the, 2018, 5, 380-381.	7.4	3
135	When the Label Does Not Match the Content of a Trial: "Wellâ€Being Therapy―in Posttraumatic Stress Disorder: Commentary on Radstaak etÂal. (2020). Journal of Traumatic Stress, 2021, 34, 467-469.	1.8	3
136	<i>Psychotherapy and Psychosomatics:</i> A Tribute to Peter E. Sifneos, MD (1920–2008). Psychotherapy and Psychosomatics, 2009, 78, 328-329.	8.8	2
137	Are the Same Medications that Are Used in the Acute Treatment of Depression the Most Suitable for Preventing Relapse?. Journal of Clinical Psychopharmacology, 2021, 41, 617-619.	1.4	2
138	Prescribing Pharmacotherapy for Major Depressive Disorder: How Does a Clinician Decide?. Biomedicine Hub, 2021, 6, 118-121.	1.2	2
139	Sulpiride and Tardive Dyskinesia. CNS Drugs, 1995, 3, 237.	5.9	1
140	Low impact. Nature, 1996, 382, 750-750.	27.8	1
141	Rating well-being and distress. , 2000, 16, 55.		1
142	Psychiatric symptomatology in secondary amenorrhea. Stress and Health, 1986, 2, 191-193.	0.5	0
143	Reply to Alacreu-Crespo et al Psychotherapy and Psychosomatics, 2020, 89, 324-325.	8.8	0
144	Incorporating the Insights of Psychotherapy Research in Everyday Practice. , 0, , 135-136.		0